Spherix Global Insights

August 16, 2017

RealTime Dynamix™: Atopic Dermatitis US Q3

Atopic dermatitis (AD), the most common form of eczema affecting 5 to 20% of the worldwide population, is a chronic inflammatory disease often presenting as a skin rash. Moderate-to-severe AD is characterized by rashes often covering much of the body, and can include intense itching and dryness, crusting, redness, and oozing which can be debilitating. Until now, there have been few options to treat more severe forms of AD, but with the approval of dupilumab, an IL-4 blocker, dermatologists have their first FDA approved biologic option to battle this disease. A host of other biologics and novel small molecules are in the pipeline and, as a result, the treatment paradigm for AD is expected to undergo a monumental shift over the next two to three years.

The RealTime Dynamix™: Atopic Dermatitis (US) report series provides a detailed and timely look at current and future trends in the AD market, and the effects of the future shifting landscape. The quarterly releases allow for close monitoring and trending of key performance metrics. In addition to the fixed trended measures, the report also includes variable content addressing key current issues updated quarterly. The rapid fieldto-insight turnaround time, highly relevant content, and unparalleled knowledge of the dermatology market make this an essential tool for companies competing in the space, as well as those with near-term plans to enter it.

Download Report Overview

About Spherix Global Insights
Spherix Global Insights is a business intelligence and market research company, specializing in renal, autoimmune, neurologic and rare disease markets. Our aim is to apply our commercial experience and unique relationships within core specialty markets to translate data into insight, enabling our clients to make smarter business decisions.

For more information contact:
Telephone: (800) 661-0571
Email: [email protected]
www.spherixglobalinsights.com